Robert Sidonio
Pediatric Hematology-Oncology · Atlanta, GANPI 1518000900
Payments from drug & device makers
Across 771 payments — averaging $3400.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1.3M
- Shire North American Group Inc$190K
- Octapharma USA, Inc.$171K
- Sanofi$145K
- Novo Nordisk AS$144K
- Genentech, Inc.$115K
- plus $584K from 23 others
Across 18 payments — averaging $1574.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$11K
- HEMA Biologics, LLC$8K
- Octapharma USA, Inc.$7K
- Bioverativ Therapeutics Inc.$3K
What the payments were for
- Consulting fees$386,82746%
- Speaking & faculty fees$311,28337%
- Travel & lodging$120,53014%
- Food & beverage$14,3372%
- Education$6100%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $1,273,363 |
| Shire North American Group Inc | 43 | $189,735 |
| Octapharma USA, Inc. | 120 | $170,669 |
| Sanofi | 83 | $145,478 |
| Novo Nordisk AS | 20 | $143,572 |
| Genentech, Inc. | 14 | $114,762 |
| HEMA Biologics, LLC | 86 | $108,905 |
| Grifols Shared Services North America, Inc. | 1 | $76,950 |
| Novo Nordisk | 39 | $65,082 |
| Bioverativ Therapeutics Inc. | 50 | $60,008 |
| Genentech USA, Inc. | 70 | $54,201 |
| Swedish Orphan Biovitrum AB | 17 | $34,826 |
| Pfizer | 26 | $31,595 |
| Bayer | 28 | $29,859 |
| F. Hoffmann-la Roche AG | 18 | $29,821 |
| Biomarin Pharmaceutical Inc. | 31 | $29,372 |
| Spark Therapeutics, Inc. | 9 | $14,834 |
| Sanofi-aventis U.S. LLC | 9 | $14,731 |
| Novo Nordisk Health Care AG | 10 | $13,563 |
| Pharmacosmos Therapeutics Inc. | 14 | $5,530 |
| Aptevo Therapeutics Inc | 14 | $3,791 |
| Takeda Pharmaceutical Company, Limited | 1 | $3,000 |
| CSL Behring | 5 | $2,959 |
| Sysmex America, Inc. | 1 | $2,500 |
| Daiichi Sankyo Inc. | 1 | $1,080 |
| Regeneron | 2 | $976 |
| Diagnostica Stago SAS | 1 | $466 |
| Eagle Pharmaceuticals, Inc. | 1 | $400 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALPROLIX$85,610
- SevenFact$82,776
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$81,484
- HEMLIBRA$74,970
- NUWIQ$42,252
- ELOCTATE$33,824
- FEIBA$24,869
- VONVENDI$13,810
- HYMPAVZI$13,500
- ADYNOVATE$12,042
- Jivi$10,512
- Non-Covered Product$9,401
- NO PRODUCT DISCUSSED$8,160
- Monoferric$5,418
- REBINYN$5,323
- Roctavian$4,850
- FIBRYGA & BALFAXAR$4,363
- ADVATE$4,250
- IXINITY$3,715
- CEPROTIN$3,263
How this compares
$2,622,053 in reported general payments places this provider in the 95th percentile of 74 pediatric hematology-oncology providers in Georgia.
See all pediatric hematology-oncology providers in Georgia →
Other pediatric hematology-oncology in Atlanta
- Sharon CastellinoAtlanta$4.7M
- William CashAtlanta$2.5M
- Carolyn BennettAtlanta$1.7M
- Vivien SheehanAtlanta$1.5M
- Carlton DampierAtlanta$1.2M
- Muna QayedAtlanta$947K
- Amy TangAtlanta$819K
- Shanmuganathan ChandrakasanAtlanta$485K
- Lakshmanan KrishnamurtiAtlanta$395K
- Wilbur LamAtlanta$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.